DERM
Price
$5.12
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
126 days until earnings call
DRMA
Price
$1.23
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

DERM vs DRMA

Header iconDERM vs DRMA Comparison
Open Charts DERM vs DRMABanner chart's image
Journey Medical
Price$5.12
Change-$0.00 (-0.00%)
Volume$82.31K
CapitalizationN/A
Dermata Therapeutics
Price$1.23
Change-$0.00 (-0.00%)
Volume$50.28K
CapitalizationN/A
DERM vs DRMA Comparison Chart
Loading...
DERM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DRMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
DERM vs. DRMA commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a Hold and DRMA is a Sell.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (DERM: $5.08 vs. DRMA: $1.19)
Brand notoriety: DERM: Notable vs. DRMA: Not notable
DERM represents the Pharmaceuticals: Other, while DRMA is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: DERM: 44% vs. DRMA: 8%
Market capitalization -- DERM: $73.35M vs. DRMA: $1.8M
DERM [@Pharmaceuticals: Other] is valued at $73.35M. DRMA’s [@Biotechnology] market capitalization is $1.8M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.45B. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 0 FA rating(s) are green whileDRMA’s FA Score has 1 green FA rating(s).

  • DERM’s FA Score: 0 green, 5 red.
  • DRMA’s FA Score: 1 green, 4 red.
According to our system of comparison, DERM is a better buy in the long-term than DRMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 3 TA indicator(s) are bullish while DRMA’s TA Score has 3 bullish TA indicator(s).

  • DERM’s TA Score: 3 bullish, 7 bearish.
  • DRMA’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, DRMA is a better buy in the short-term than DERM.

Price Growth

DERM (@Pharmaceuticals: Other) experienced а -11.03% price change this week, while DRMA (@Biotechnology) price change was -11.27% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +56.51%. For the same industry, the average monthly price growth was -6.12%, and the average quarterly price growth was -10.57%.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +6.14%.

Reported Earning Dates

DERM is expected to report earnings on Mar 20, 2025.

DRMA is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Pharmaceuticals: Other (+56.51% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DERM($73.4M) has a higher market cap than DRMA($1.8M). DERM YTD gains are higher at: -10.590 vs. DRMA (-86.556). DERM has higher annual earnings (EBITDA): -5.69M vs. DRMA (-10.12M). DERM has more cash in the bank: 24.7M vs. DRMA (4.95M). DERM has less debt than DRMA: DERM (131K) vs DRMA (175K). DERM has higher revenues than DRMA: DERM (79.9M) vs DRMA (0).
DERMDRMADERM / DRMA
Capitalization73.4M1.8M4,087%
EBITDA-5.69M-10.12M56%
Gain YTD-10.590-86.55612%
P/E RatioN/AN/A-
Revenue79.9M0-
Total Cash24.7M4.95M499%
Total Debt131K175K75%
FUNDAMENTALS RATINGS
DERM: Fundamental Ratings
DERM
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
57
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
60
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DERMDRMA
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
87%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
DERM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DRMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PGC37.040.31
+0.84%
Peapack-Gladstone Financial Corp
RY123.15-0.74
-0.60%
Royal Bank of Canada
CLDX26.84-0.17
-0.63%
Celldex Therapeutics
BERY67.00-0.89
-1.31%
Berry Global Group
HYPR0.87-0.07
-7.00%
Hyperfine

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and CHRS have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and CHRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
-5.50%
CHRS - DERM
27%
Poorly correlated
-5.40%
VXRT - DERM
24%
Poorly correlated
-2.24%
DRMA - DERM
22%
Poorly correlated
-4.64%
ITRM - DERM
22%
Poorly correlated
-4.39%
ELAN - DERM
21%
Poorly correlated
+0.50%
More

DRMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with IRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRMA
1D Price
Change %
DRMA100%
-4.64%
IRON - DRMA
43%
Loosely correlated
-0.36%
CDMO - DRMA
42%
Loosely correlated
-0.25%
PIRS - DRMA
32%
Poorly correlated
-0.12%
KRRO - DRMA
28%
Poorly correlated
-15.55%
AVXL - DRMA
27%
Poorly correlated
-1.44%
More